Literature DB >> 1337070

Erythema migrans: comparison of treatment with azithromycin, doxycycline and phenoxymethylpenicillin.

F Strle1, E Ruzic, J Cimperman.   

Abstract

Azithromycin, doxycycline and phenoxymethylpenicillin were compared in a prospective, randomized study of 64 patients with typical erythema migrans. Twenty patients were treated with oral azithromycin, 250 mg bd for two days followed by 250 mg od for eight days, 21 patients were given phenoxymethylpenicillin 1 million IU tds for 14 days and 23 patients received doxycycline, 100 mg bd for 14 days. All patients were followed up for 24 months. There were no significant differences between the groups with respect to the persistence of cutaneous lesions after starting treatment; the mean durations were 10.5 days in the penicillin group, 8.8 days in the doxycycline group and 8.6 days in the azithromycin group. There were statistically significant differences in terms of the resolution of associated local and/or systemic symptoms. The response time was shortest in patients treated with azithromycin. Two patients who received phenoxymethylpenicillin and two given doxycycline subsequently developed major manifestations of Lyme borreliosis; these did not occur in patients receiving azithromycin. Although azithromycin has been shown to be effective in the treatment of erythema migrans, further studies will be needed to determine the optimal dosage and duration of therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1337070     DOI: 10.1093/jac/30.4.543

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

Review 1.  The Jarisch-Herxheimer Reaction After Antibiotic Treatment of Spirochetal Infections: A Review of Recent Cases and Our Understanding of Pathogenesis.

Authors:  Thomas Butler
Journal:  Am J Trop Med Hyg       Date:  2016-10-24       Impact factor: 2.345

Review 2.  Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease.

Authors:  Daniel J Cameron; Lorraine B Johnson; Elizabeth L Maloney
Journal:  Expert Rev Anti Infect Ther       Date:  2014-07-30       Impact factor: 5.091

Review 3.  Systematic review of the treatment of early Lyme disease.

Authors:  P S Loewen; C A Marra; F Marra
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

Review 4.  Controversies in the use of antimicrobials for the prevention and treatment of Lyme disease.

Authors:  G P Wormser
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

5.  Solitary erythema migrans in children: comparison of treatment with clarithromycin and amoxicillin.

Authors:  Tea Nizič; Eva Velikanje; Eva Ružić-Sabljić; Maja Arnež
Journal:  Wien Klin Wochenschr       Date:  2012-07-04       Impact factor: 1.704

Review 6.  Efficacy and Safety of Antibiotic Therapy in Early Cutaneous Lyme Borreliosis: A Network Meta-analysis.

Authors:  Gabriel Torbahn; Heidelore Hofmann; Gerta Rücker; Karin Bischoff; Michael H Freitag; Rick Dersch; Volker Fingerle; Edith Motschall; Joerg J Meerpohl; Christine Schmucker
Journal:  JAMA Dermatol       Date:  2018-11-01       Impact factor: 10.282

7.  Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans.

Authors:  F Strle; V Maraspin; S Lotric-Furlan; E Ruzić-Sabljić; J Cimperman
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

Review 8.  Treatment failure in erythema migrans--a review.

Authors:  K Weber
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

9.  Erythema migrans: three weeks treatment for prevention of late Lyme borreliosis.

Authors:  F Breier; G Kunz; H Klade; G Stanek; E Aberer
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

10.  Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings.

Authors:  F Strle; V Preac-Mursic; J Cimperman; E Ruzic; V Maraspin; M Jereb
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.